{"prompt": "['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '6.1.1.', 'Rationale for Study Design, Dose(s) and Comparator(s)', 'This is randomized, double-blind, parallel-group, placebo-controlled study conducted in', 'approximately 450 subjects with SAR. Subjects will be randomized to 1 of the 2 treatment', 'groups in a 1:1 ratio. Randomization will be performed centrally using Interactive Voice', 'Response System (IVRS)/Interactive Web Response System (IWRS).', 'The overall study design is consistent with other similar studies reported in the literature', '(Berger et al, 2016; Storms et al, 2013). Furthermore, the overall study design is also based on', 'the US Food and Drug Administration (FDA) guidance document: Allergic Rhinitis: Developing', 'Drug Products for Treatment - Guidance for Industry (Draft Guidance) (FDA Guidance for', 'Industry, 2000; FDA Guidance for Industry, 2016).', 'This current study is planned to evaluate the superiority of GSP 301 NS to placebo NS. The', 'placebo used in the study is formulated in the same vehicle as GSP 301 NS and all the NS bottles', 'are identical in appearance. Thus, other than the active component, there are no other differences', 'in the formulation or the bottle of each treatment.', '6.1.2.', 'Estimated Duration of Subject Participation', 'The expected total duration of subject participation in the study is up to 27 days. This includes a', 'placebo run-in period of 7 to 10 days and 14 days of treatment period, with allowable window', 'periods for the study visits (see schedule of assessments, Table 2).', '6.2.', 'Number of Subjects', 'A', 'total of approximately 450 subjects (225 subjects randomized to each treatment group) are', 'planned to be randomized in the study.', '6.3.', 'Treatment Assignment', 'Study participation begins once written informed consent is obtained (see Section 16.3 for', 'details).', 'This is a multicenter, randomized, double-blind, placebo-controlled study. Subjects will be', 'randomized in a 1:1 ratio. Randomization will be performed centrally using Interactive Voice', 'Response System (IVRS)/Interactive Web Response System (IWRS).', 'The procedure for using the IVRS/IWRS will be provided to each site separately.', 'Details of unblinding in the event of a medical emergency are provided in Section 8.4.1.', '6.4.', 'Dose Adjustment Criteria', 'Not applicable.', '6.5.', 'Criteria for Study Termination', 'The Sponsor reserves the right to discontinue the study for medical reasons or any other reason at', 'any time. If a study is prematurely terminated or suspended, the Sponsor will promptly inform', 'the Investigators/Institutions and regulatory authorities of the termination or suspension and the', 'Glenmark', 'CONFIDENTIAL', 'Page 30 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', 'reason(s) for the termination or suspension. The Institutional Review Board (IRB)/independent', 'Ethics Committee (IEC) will also be informed promptly and provided with the reason(s) for the', 'termination or suspension by the Sponsor or by the Investigator/Institution, as specified by the', 'applicable regulatory requirement(s).', 'The Investigator reserves the right to discontinue participation in the study should his/her', 'judgment SO dictate. If the Investigator terminates or suspends a study without prior agreement', 'of the Sponsor, the Investigator should inform the Institution where applicable, and the', 'Investigator/Institution should promptly inform the Sponsor and the IRB/IEC and provide the', 'Sponsor and the IRB/IEC with a detailed written explanation of the termination or suspension.', 'Study records must be retained as noted in Section 17.', '6.6.', 'End of the Study', 'The end of the study (study completion) is defined as the date of the last protocol-specified', 'visit/assessment (including telephone contact) for the last subject in the study. All materials or', 'supplies provided by the Sponsor will be returned to the Sponsor or designee upon study', 'completion, as directed by the site monitor. The Investigator will notify the IRB/IEC when the', 'study has been completed.', '7.', 'SELECTION AND WITHDRAWAL OF SUBJECTS', '7.1.', 'Subject Inclusion Criteria', 'Subjects eligible for enrolment in the study must meet all of the following criteria:', '1. Male or non-pregnant female subjects aged >6 to <12 years, at the Screening Visit', '(Visit 1).', '2. Signed informed consent/assent form (subject and parent/caregiver/legal guardian),', 'which meets all criteria of the current Food and Drug Administration/local regulations.', '3. Documented clinical history of SAR (for at least 2 years preceding the Screening Visit', '[Visit 1]) with exacerbations (clinical evidence of active symptoms) during the spring or', 'fall allergy seasons for the relevant seasonal allergen (eg, tree/grass pollen or ragweed', 'pollen). SAR must have been of sufficient severity to have required treatment (either', \"continuous or intermittent) in the past, and in the Investigator's judgment, is expected to\", 'require treatment throughout the study period.', '4. Demonstrated sensitivity to at least 1 seasonal allergen (eg, tree/grass pollen or ragweed', 'pollen) known to induce SAR through a documented positive skin prick test (wheal', 'diameter at least 5 mm greater than the negative control) to a relevant seasonal allergen.', 'Documentation of a positive result within 12 months prior to the Screening Visit (Visit 1)', \"is acceptable. The subject's positive allergen must be consistent with the medical history\", 'of SAR. Additionally, the subject is expected to be adequately exposed to the SAR', 'allergen that he/she has tested positive for the entire duration of the study.', '5. A 12-hour reflective Total Nasal Symptom Score (rTNSS) value of >6 (out of a possible', '12) for the morning (AM) assessment at the Screening Visit (Visit 1).', 'Glenmark', 'CONFIDENTIAL', 'Page 31 of 90']\n\n###\n\n", "completion": "END"}